IP Library › Granted Patent US 12,583,866
Granted Patent B2
US 12,583,866 · App. 17/928,949 · Granted Mar 24, 2026

Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists

Inventors: Jing Li (Beijing, CN); Fengtao Song (Beijing, CN); Zhiwei Wang (Beijing, CN)
Assignee: BeOne Medicines I GmbH
C07D498/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,583,866
App. No.
17/928,949
Granted
Mar 24, 2026
Kind
B2
Abstract

Disclosed herein are novel 2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine or 1,2,3,4-tetrahydropyrido[2,3-b][1,4]oxazepine derivatives used as antagonists of IAPs (Inhibitors Apoptosis Proteins), also known as Smac mimetics. Disclosed herein is the use of these antagonists for inducing or sensitizing cells to the induction of apoptotic cell death, and the use of such compounds for treating proliferative disease such as cancer.

Claims (35)

1 . A compound selected from

or a pharmaceutically acceptable salt or tautomer thereof.

2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof, and at least one pharmaceutically acceptable carrier or excipient.

3 . A method of treating a disease responsive to inhibition of cIAPs, comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.

4 . A method of treating cancer modulated by cIAPs, comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.

5 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

6 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

12 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

16 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

17 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

18 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

19 . The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2025
From: BEIGENE, LTD.
To: BEONE MEDICINES I GMBH
Reel/Frame 073116/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2022
From: LI, JING; SONG, FENGTAO; WANG, ZHIWEI
To: BEIGENE, LTD.
Reel/Frame 062065/0494 →
Priority Claims (3)
WO PCT/CN2020/094309 · Jun 4, 2020 · international
WO PCT/CN2020/119974 · Oct 9, 2020 · international
WO PCT/CN2020/134610 · Dec 8, 2020 · international
Continuity (1)
Related Publication 20230219975A1 · Jul 13, 2023
References Cited (45)
US 20160108039A1 · Allerheiligen et al. · 2016 [cited by applicant]
CN 101801962 · 2010 [cited by applicant]
CN 104945345 · 2015 [cited by applicant]
CN 105408331 · 2016 [cited by applicant]
EP 2266989 · 2010 [cited by applicant]
WO 2009007748 · 2009 [cited by applicant]
WO 2012143726 · 2012 [cited by applicant]
WO 2014060767 · 2014 [cited by applicant]
WO 2014060770 · 2014 [cited by applicant]
WO 2015092420 · 2015 [cited by applicant]
WO 2018237370 · 2018 [cited by applicant]
Johnson, Christopher N., et al. “A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl) methyl]-5-(hydroxymethyl)-3, 3-dimethyl-1 H, 2 H, 3 … [cited by applicant]
Fontanella, L., “New synthesis of 1-phenyl-2,6-dimethylpiperazine”, Il Farmaco, Elsevier France * Editions Scientifiques et Medicales, FR, FR , (Dec. 31, 1982), vol. 37, No. fasc. 6, ISSN 0014-827X, 1 page, XP009546736. [cited by applicant]
Cohen, “Protein kinases—the major drug targets of the twenty-first century?”, Nature, 1: 309-315 (2002). [cited by applicant]
Gaestel et al., “Protein Kinases as Small Molecule Inhibitor Targets in Inflammation”, Curr. Med. Chem. 14: 2214-223 (2007). [cited by applicant]
Grimminger et al. “Targeting non-malignant disorders with tyrosine kinase inhibitors”, Nat. Rev. Drug Disc. 9 (12) : 956-970 (2010). [cited by applicant]
Cohen, “The role of protein phosphorylation in human health and disease,” Eur. J. Biochem., 268: 5001-5010 (2001). [cited by applicant]
Cohen, 2005, Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems, Handbook of Experimental Pharmacology, Springer Berlin Heidelberg, 167:1-7. [cited by applicant]
Kerr, J.F., et al., “Apoptosis: a Basic Biological Phenomenon With Wide-Ranging Implications in Tissue Kinetics,” Br J Cancer, 1972, 26, 239-257. [cited by applicant]
Nicholson, D.W., et al., “From bench to clinic with apoptosis-based therapeutic agents”, Nature, 2000, 407, 810-816. [cited by applicant]
Hanahan, D., et al., “The Hallmarks of Cancer,” cell 2000, 100, 57-70. [cited by applicant]
Hanahan, Douglas, and Robert A. Weinberg. “Hallmarks of cancer: the next generation.” cell 144.5 (2011): 646-674. [cited by applicant]
Elmore, S., “Aptosis: A Review of Programmed Cell Death,” Toxicol Pathol, 2007, 35, 495-516. [cited by applicant]
Birnbaum, M.J., et al., “An Apoptosis-Inhibiting Gene from a Nuclear Polyhedrosis Virus Encoding a Polypeptide with Cys/His Sequence Motifs,” J Virol, 1994, 68, 2521-2528. [cited by applicant]
Yang, Y.L., “The IAP family: endogenous caspase inhibitors with multiple biological activities,” Cell Res, 2000, 10, 169-177. [cited by applicant]
Salvesen, G.S., et al., “IAP Proteins: Blocking the Road to Death's Door”, Nat Rev Mol Cell Bio, 2002, 3, 401-410. [cited by applicant]
Derakhshan, A., et al., “Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways,” Clin Cancer Res, 2017, 23, 1379-1387. [cited by applicant]
Samuel T., et al., “Distinct BIR Domains of cIAP1 Mediate Binding to and Ubiquitination of Tumor Necrosis Factor Receptor-associated Factor 2 and Second Mitochondrial Activator of Caspases,” J Biol Chem, 2006, 281, 1080… [cited by applicant]
Vince J.E., et al., “TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF-kB and to Prevent TNF-induced Apoptosis,” J Biol Chem, 2009, 284, 35906-35915. [cited by applicant]
Wang C., et al., “TAK1 is a ubiquitin-dependent kinase of MKK and IKK”, Nature, 2001, 412, 346-351. [cited by applicant]
Deveraux Q. L., et al., “X-linked IAP is a direct inhibitor of cell-death proteases”, Nature, 1997, 388, 300-304. [cited by applicant]
Chai J., et al., “Structural Basis of Caspase-7 Inhibition by XIAP,” Cell, 2001, 104, 769-780. [cited by applicant]
Riedl S.J., et al., “Structural Basis for the Inhibition of Caspase-3 by XIAP,” Cell, 2001, 104, 791-800. [cited by applicant]
Shiozaki E.N., et al., “Mechanism of XIAP-Mediated Inhibition of Caspase-9,” Mol Cell, 2003, 11, 519-527. [cited by applicant]
Che, Xiangyu, et al. “Nuclear cIAP1 overexpression is a tumor stage-and grade-independent predictor of poor prognosis in human bladder cancer patients.” Urologic Oncology: Seminars and Original Investigations. vol. 30. … [cited by applicant]
Yang C., et al., “LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC,” J Exp Clin Cancer Res, 2016, 17 pages. [cited by applicant]
Gu H., et al., “Aging exacerbates mortality of Acinetobacter baumannii pneumonia and reduces the efficacies of antibiotics and vaccine,” Aging (Albany NY) , 2018, 10, 1597-1608. [cited by applicant]
Du C., et al., “Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition,” Cell, 2000, 102, 33-42. [cited by applicant]
Verhagen A.M., et al., “Identification of Diablo, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins” Cell, 2000, 102, 43-53. [cited by applicant]
Chai J., et al., “Structural and biochemical basis of apoptotic activation by Smac/Diablo,” Nature, 2000, 406, 855-862. [cited by applicant]
Dueber E.C., et al., “Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination”, Science, 2011, 334, 376-380. [cited by applicant]
Micheau, O., et al., “Induction of TNF Receptor I-Mediated Apoptosis vai Two Sequential Signaling Complexes,” Cell, 2003, 114, 181-190. [cited by applicant]
Liu Z., et al., Nature, “Sturctural basis for binding of Smac/Diablo to the XIAP BIR3 domain”, 2000, 408, 1004-1008. [cited by applicant]
Dieter Enders, et al., “(S,S)-3,5-Dimethylmorpholine, a Novel C2-Symmetric Auxiliary. First Application in [4+2]-Cycloadditions Leading to 4-Oxohexahydropyridazine Derivatives”, Synthesis, 1994 (01) , 66-72. [cited by applicant]
G. Cignarella et al., “Antiadrenergic substances”, Gazz. Chim. Ital., 1962, 92, 1 page. [cited by applicant]